Skip to main navigation Skip to search Skip to main content

Clinical comparison of cryoballoon ablation and radiofrequency ablation in the treatment of persistent atrial fibrillation

  • Jiaxin Luan
  • , Xinyu Zhang
  • , Zixuan Meng
  • , Jianqing She
  • , Rui Shi
  • , Yixin Zhao
  • , Lihong Fan
  • , Yang Liu
  • , Yue Wu
  • , Hongbing Li
  • The First Affiliated Hospital of Xi’an Jiaotong University
  • The Ninth Hospital of Xi'an
  • Xi'an Jiaotong University
  • Royal Brompton and Harefield NHS Foundation Trust

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: To analyze and compare the efficacy and safety of cryoballoon catheter ablation (CBA) and radiofrequency ablation (RFA) in the first treatment of patients with persistent atrial fibrillation (PerAF). Methods: 116 patients with PerAF who underwent the first-time catheter ablation were enrolled retrospectively, including 56 patients in CBA group and 60 patients in RFA group. The primary endpoint was symptomatic onset after 3 months of ablation or occurrence of atrial arrhythmia (ATA) with any documented duration more than 30 s. The secondary endpoints were perioperative complications and re-ablation 3 month after procedure. Results: No remarkable difference existed between CBA group and RFA group in the recurrence rate one year after operation (CBA 16.1% vs. RFA 23.3%, P = 0.360). Additionally, the complication rates were similar between the two groups (CBA 25.0% vs. RFA 35.0%, P = 0.312). Conclusion: In this real-world study, the effectiveness and overall safety of CBA and RFA in the treatment of PerAF were comparable.

Original languageEnglish
Article number1769845
JournalFrontiers in Cardiovascular Medicine
Volume13
DOIs
StatePublished - 2026
Externally publishedYes

Keywords

  • cryoballoon catheter ablation
  • efficacy
  • persistent atrial fibrillation
  • radiofrequency ablation
  • safety

Fingerprint

Dive into the research topics of 'Clinical comparison of cryoballoon ablation and radiofrequency ablation in the treatment of persistent atrial fibrillation'. Together they form a unique fingerprint.

Cite this